Click here to access the analysis showing your margins on both the above product and the alternative funded product.

Bimatoprost-Actavis will be displaying a part charge on your computer system when dispensing this product. However as per previous notification 21 January 2019, ProPharma / PWR have been supplying this product at less than the Pharmaceutical Schedule price and therefore you are able to zero this part charge.

We have limited stock available (with more arriving later this week) of Bimatoprost-Actavis which we are selling as shown at $1.10 (plus GST) on a first in, first served basis. Once sold, we will automatically replace to Bimatoprost-Multichem.

This is another opportunity to increase your margin on a low value high volume product without risk.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author